Clinical Trials Show Sun Pharma's Anti-Osteoarthritis Injection Delivers Long-Lasting Pain Relief

Sun Pharmaceutical Industries and Moebius Medical have revealed data showing that pain relief in patients with symptomatic knee OA lasts for 26 weeks following an MM-II injection. These findings, presented at EULAR 2024, come from a randomized, controlled Phase 2b clinical trial (NCT04506463).An abstract presenting the data, named as “Duration of Clinically Meaningful Analgesic Response to Intra -Articular MM-II, A Novel Suspension of Large, Empty, Multilamellar Liposomes, in Patients with Painful Knee Osteoarthritis: Analysis from a 26-Week Phase 2b Randomized Controlled Trial”, was presented by Philip G. Conaghan, a Professor of Musculoskeletal Medicine at the University of Leeds and the Director of the NIHR Leeds Biomedical Research Centre.

Conaghan said that “Given the limitations of many current therapies, there is an urgent need for more therapeutic treatment options for patients with painful osteoarthritis. Data from the 3mL dose of MM-II in this trial demonstrate MM-II’s potential to offer durable and meaningful pain relief with good tolerability.”

MM-II is an innovative non-opioid product featuring a unique suspension of large, empty, multilamellar liposomes designed to minimize joint friction and wear, thereby alleviating joint pain. Sun Pharma and Moebius Medical, collaborating on the development of this product, have revealed their plans to begin a Phase 3 clinical trial and pursue a CE Mark for approval in the European Union. “With over 100 million people currently suffering from joint pain, there is a significant unmet need for additional OA therapies. This analysis from our clinical trial is further confirmation of the potential role that MM-II will be able to play in improving painful OA treatment, said Abhay Gandhi, CEO - North America Business, Sun Pharma.

Moshe Weinstein, CEO of Moebius Medical, added, “As more data become available, we continue to see MM-II’s potential as a safe and effective alternative to today’s OA treatments. We look forward to continuing development of our lead candidate with our partners at Sun Pharma.”